Pages that link to "Q64364605"
Jump to navigation
Jump to search
The following pages link to William Jeffery Sandborn (Q64364605):
Displaying 50 items.
- Inflammatory bowel disease: clinical aspects and established and evolving therapies (Q21957029) (← links)
- Management of Crohn's disease in adults (Q22242349) (← links)
- Natalizumab Induction and Maintenance Therapy for Crohn's Disease (Q22250890) (← links)
- A simple classification of Crohn's disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 (Q22252901) (← links)
- Antibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressives (Q24185835) (← links)
- MRI scoring indices for evaluation of disease activity and severity in Crohn’s disease (Q24186977) (← links)
- Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis (Q24187044) (← links)
- Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis (Q24187707) (← links)
- Placebo response and remission rates in randomized trials of induction and maintenance therapy for ulcerative colitis (Q24187737) (← links)
- Histologic scoring indices for evaluation of disease activity in ulcerative colitis (Q24194674) (← links)
- Endoscopic scoring indices for evaluation of disease activity in Crohn’s disease (Q24201734) (← links)
- Biomarkers for assessing disease activity in inflammatory bowel disease (Q24202614) (← links)
- Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis (Q24234806) (← links)
- Endoscopic scoring indices for evaluation of disease activity in Crohn’s disease (Q26470550) (← links)
- Placebo response and remission rates in randomised trials of induction and maintenance therapy for Crohn’s disease (Q26471222) (← links)
- Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases (Q27008246) (← links)
- Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions (Q28087314) (← links)
- Lymphocytic colitis: clinical features, treatment, and outcomes (Q28194164) (← links)
- Diagnosis and management of pouchitis (Q28208636) (← links)
- Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study (Q28218907) (← links)
- Certolizumab pegol for the treatment of Crohn's disease (Q28236746) (← links)
- Health-related quality of life during natalizumab maintenance therapy for Crohn's disease (Q28258882) (← links)
- Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials (Q28266279) (← links)
- Crohn's disease (Q28273481) (← links)
- Infliximab for induction and maintenance therapy for ulcerative colitis (Q28285876) (← links)
- Anti-interleukin-12 antibody for active Crohn's disease (Q28292686) (← links)
- Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial (Q28296771) (← links)
- Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide (Q28361611) (← links)
- Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease (Q28361615) (← links)
- Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease (Q28393838) (← links)
- Risk of Biologic Therapy-Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn's Disease (Q28538974) (← links)
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease (Q30054715) (← links)
- Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes (Q30239737) (← links)
- Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management (Q30245054) (← links)
- Evolving Concepts in Phases I and II Drug Development for Crohn's Disease (Q30248641) (← links)
- Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. (Q30355181) (← links)
- Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. (Q30662026) (← links)
- Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. (Q30679247) (← links)
- Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. (Q30844786) (← links)
- Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial (Q30984504) (← links)
- Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study (Q31113830) (← links)
- Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices (Q31148096) (← links)
- Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials (Q33343338) (← links)
- Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease (Q33412103) (← links)
- Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis (Q33497983) (← links)
- Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data (Q33541428) (← links)
- Update on Janus kinase antagonists in inflammatory bowel disease (Q34030650) (← links)
- Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) (Q34047972) (← links)
- Validated gene expression biomarker analysis for biopsy-based clinical trials in ulcerative colitis (Q34084800) (← links)
- Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis (Q34143725) (← links)